Background: Short-term weight gains and losses are associated with a lower and higher mortality risk, respectively, in patients undergoing hemodialysis (HD). However, little is known about their association with the risk of subsequent hospitalization. Methods: In a prospective cohort of 1,804 HD patients aged ≥65 years enrolled in the Japanese Dialysis Outcomes and Practice Patterns Study phases 3 (2005–2008) and 4 (2009–2011), we examined the associations between changes in body mass index (BMI) over a 4-month baseline period (<–3%, –3 to <–1%, –1 to <1% [reference], 1 to <3%, and ≥3%) and subsequent risk of all-cause, cardiovascular, and noncardiovascular hospitalization using Cox models with adjustment for potential confounders. Results: During a median follow-up of 1.2 years, we noted 1,028 incident hospitalizations for any cause, including 275 and 753 hospitalizations for cardiovascular and noncardiovascular causes, respectively. An L-shaped association was observed between BMI change and all-cause hospitalization. The multivariable-adjusted hazard ratios (HRs; 95% CI) of all-cause hospitalization associated with BMI changes of <–3%, –3 to <–1%, 1 to <3%, and ≥3% (vs. –1 to <1%) were 1.29 (1.01–1.65), 1.22 (0.98–1.51), 1.04 (0.83–1.29), and 1.10 (0.83–1.45), respectively. Qualitatively similar associations were present for cardiovascular-related hospitalization (corresponding HRs [95% CI]: 1.58 [1.06–2.37], 1.09 [0.75–1.58], 0.99 [0.72–1.36], and 0.91 [0.51–1.64], respectively) but not for noncardiovascular-related hospitalization (corresponding HRs [95% CI]: 1.19 [0.90–1.57], 1.26 [0.99–1.59], 1.06 [0.84–1.35], and 1.18 [0.86–1.63], respectively). Conclusions: Decreases in BMI over a relatively short-term period were independently associated with higher risk of subsequent hospitalization, particularly cardiovascular-related hospitalization, among elderly HD patients.

Keywords:
Body mass index, Hemodialysis, Hospitalization, Cardiovascular disease, Infection
1.
Chertow GM, Hsu CY, Johansen KL: The enlarging body of evidence: obesity and chronic kidney disease. J Am Soc Nephrol 2006; 17: 1501–1502.
2.
Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R: Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373: 1083–1096.
3.
Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL: The effect of age on the association between body-mass index and mortality. N Engl J Med 1998; 338: 1–7.
4.
Grabowski DC, Ellis JE: High body mass index does not predict mortality in older people: analysis of the longitudinal study of aging. J Am Geriatr Soc 2001; 49: 968–979.
5.
Oreopoulos A, Kalantar-Zadeh K, Sharma AM, Fonarow GC: The obesity paradox in the elderly: potential mechanisms and clinical implications. Clin Geriatr Med 2009; 25: 643–659, viii.
6.
Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA: Body mass index and mortality in heart failure: a meta-analysis. Am Heart J 2008; 156: 13–22.
7.
Oreopoulos A, Ezekowitz JA, McAlister FA, Kalantar-Zadeh K, Fonarow GC, Norris CM, Johnson JA, Padwal RS: Association between direct measures of body composition and prognostic factors in chronic heart failure. Mayo Clin Proc 2010; 85: 609–617.
8.
Park J, Ahmadi SF, Streja E, Molnar MZ, Flegal KM, Gillen D, Kovesdy CP, Kalantar-Zadeh K: Obesity paradox in end-stage kidney disease patients. Prog Cardiovasc Dis 2014; 56: 415–425.
9.
Vashistha T, Mehrotra R, Park J, Streja E, Dukkipati R, Nissenson AR, Ma JZ, Kovesdy CP, Kalantar-Zadeh K: Effect of age and dialysis vintage on obesity paradox in long-term hemodialysis patients. Am J Kidney Dis 2014; 63: 612–622.
10.
Sakao Y, Ojima T, Yasuda H, Hashimoto S, Hasegawa T, Iseki K, Tsubakihara Y, Kato A: Serum creatinine modifies associations between body mass index and mortality and morbidity in prevalent hemodialysis patients. PLoS One 2016; 11:e0150003.
11.
Kalantar-Zadeh K, Streja E, Kovesdy CP, Oreopoulos A, Noori N, Jing J, Nissenson AR, Krishnan M, Kopple JD, Mehrotra R, Anker SD: The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc 2010; 85: 991–1001.
12.
Kalantar-Zadeh K, Streja E, Molnar MZ, Lukowsky LR, Krishnan M, Kovesdy CP, Greenland S: Mortality prediction by surrogates of body composition: an examination of the obesity paradox in hemodialysis patients using composite ranking score analysis. Am J Epidemiol 2012; 175: 793–803.
13.
Cabezas-Rodriguez I, Carrero JJ, Zoccali C, Qureshi AR, Ketteler M, Floege J, London G, Locatelli F, Gorriz JL, Rutkowski B, Memmos D, Ferreira A, Covic A, Teplan V, Bos WJ, Kramar R, Pavlovic D, Goldsmith D, Nagy J, Benedik M, Verbeelen D, Tielemans C, Wuthrich RP, Martin PY, Martinez-Salgado C, Fernandez-Martin JL, Cannata-Andia JB: Influence of body mass index on the association of weight changes with mortality in hemodialysis patients. Clin J Am Soc Nephrol 2013; 8: 1725–1733.
14.
Kurella M, Covinsky KE, Collins AJ, Chertow GM: Octogenarians and nonagenarians starting dialysis in the United States. Ann Intern Med 2007; 146: 177–183.
15.
Santoro D, Gitto L, Di Iorio B, Savica V, Li Vecchi M, Bellinghieri G, De Santo NG; Campanian and Sicilian Registry of Dialysis: Survival in octogenarian dialysis patients: analysis in two southern Italian regions. J Nephrol 2008; 21(suppl 13):S118–S123.
16.
Tazza L, Di Napoli A, Bossola M, Valle S, Pezzotti P, Luciani G, Di Lallo D; Lazio Dialysis Registry: Ageing of patients on chronic dialysis: effects on mortality – a 12-year study. Nephrol Dial Transplant 2009; 24: 940–947.
17.
Pisoni RL, Gillespie BW, Dickinson DM, Chen K, Kutner MH, Wolfe RA: The dialysis outcomes and practice patterns study (DOPPS): design, data elements, and methodology. Am J Kidney Dis 2004; 44: 7–15.
18.
Hayashino Y, Fukuhara S, Akiba T, Akizawa T, Asano Y, Saito S, Kurokawa K: Low health-related quality of life is associated with all-cause mortality in patients with diabetes on haemodialysis: the Japan dialysis outcomes and practice pattern study. Diabet Med 2009; 26: 921–927.
19.
Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, McAllister CJ, Shinaberger CS, Gjertson DW, Greenland S: Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis 2005; 46: 489–500.
20.
Chazot C, Gassia JP, Di Benedetto A, Cesare S, Ponce P, Marcelli D: Is there any survival advantage of obesity in southern european haemodialysis patients? Nephrol Dial Transplant 2009; 24: 2871–2876.
21.
Molnar MZ, Streja E, Kovesdy CP, Bunnapradist S, Sampaio MS, Jing J, Krishnan M, Nissenson AR, Danovitch GM, Kalantar-Zadeh K: Associations of body mass index and weight loss with mortality in transplant-waitlisted maintenance hemodialysis patients. Am J Transplant 2011; 11: 725–736.
22.
Carrero JJ, Stenvinkel P, Cuppari L, Ikizler TA, Kalantar-Zadeh K, Kaysen G, Mitch WE, Price SR, Wanner C, Wang AY, ter Wee P, Franch HA: Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the international society of renal nutrition and metabolism (ISRNM). J Ren Nutr 2013; 23: 77–90.
23.
Osborn TM, Dahlgren C, Hartwig JH, Stossel TP: Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin. Am J Physiol Cell Physiol 2007; 292:C1323–C1330.
24.
Lee PS, Waxman AB, Cotich KL, Chung SW, Perrella MA, Stossel TP: Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med 2007; 35: 849–855.
25.
Lee PS, Sampath K, Karumanchi SA, Tamez H, Bhan I, Isakova T, Gutierrez OM, Wolf M, Chang Y, Stossel TP, Thadhani R: Plasma gelsolin and circulating actin correlate with hemodialysis mortality. J Am Soc Nephrol 2009; 20: 1140–1148.
26.
Chiou TT, Liao SC, Kao YY, Lee WC, Lee YT, Ng HY, Lee PS, Lee CT: Gelsolin and progression of aortic arch calcification in chronic hemodialysis patients. Int J Med Sci 2016; 13: 92–98.
27.
Huang CX, Tighiouart H, Beddhu S, Cheung AK, Dwyer JT, Eknoyan G, Beck GJ, Levey AS, Sarnak MJ: Both low muscle mass and low fat are associated with higher all-cause mortality in hemodialysis patients. Kidney Int 2010; 77: 624–629.
28.
Johansen KL, Young B, Kaysen GA, Chertow GM: Association of body size with outcomes among patients beginning dialysis. Am J Clin Nutr 2004; 80: 324–332.
29.
Kalantar-Zadeh K, Kuwae N, Wu DY, Shantouf RS, Fouque D, Anker SD, Block G, Ko-pple JD: Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr 2006; 83: 202–210.
30.
Leinig C, Pecoits-Filho R, Nascimento MM, Goncalves S, Riella MC, Martins C: Association between body mass index and body fat in chronic kidney disease stages 3 to 5, hemodialysis, and peritoneal dialysis patients. J Ren Nutr 2008; 18: 424–429.
31.
Noori N, Kovesdy CP, Dukkipati R, Kim Y, Duong U, Bross R, Oreopoulos A, Luna A, Benner D, Kopple JD, Kalantar-Zadeh K: Survival predictability of lean and fat mass in men and women undergoing maintenance hemodialysis. Am J Clin Nutr 2010; 92: 1060–1070.
32.
Ronti T, Lupattelli G, Mannarino E: The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 2006; 64: 355–365.
33.
Shoji T, Shinohara K, Hatsuda S, Kimoto E, Fukumoto S, Emoto M, Tahara H, Koyama H, Ishimura E, Miki T, Tabata T, Nishizawa Y: Altered relationship between body fat and plasma adiponectin in end-stage renal disease. Metabolism 2005; 54: 330–334.
34.
Canaud B, Tong L, Tentori F, Akiba T, Karaboyas A, Gillespie B, Akizawa T, Pisoni RL, Bommer J, Port FK: Clinical practices and outcomes in elderly hemodialysis patients: results from the dialysis outcomes and practice patterns study (DOPPS). Clin J Am Soc Nephrol 2011; 6: 1651–1662.
35.
Nakai S, Suzuki K, Masakane I, Wada A, Itami N, Ogata S, Kimata N, Shigematsu T, Shinoda T, Syouji T, Taniguchi M, Tsuchida K, Nakamoto H, Nishi S, Nishi H, Hashimoto S, Hasegawa T, Hanafusa N, Hamano T, Fujii N, Marubayashi S, Morita O, Yamagata K, Wakai K, Watanabe Y, Iseki K, Tsubakihara Y: Overview of regular dialysis treatment in Japan (as of 31 December 2008). Ther Apher Dial 2010; 14: 505–540.
36.
Fleischmann E, Teal N, Dudley J, May W, Bower JD, Salahudeen AK: Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int 1999; 55: 1560–1567.
37.
Wolfe RA, Ashby VB, Daugirdas JT, Agodoa LY, Jones CA, Port FK: Body size, dose of hemodialysis, and mortality. Am J Kidney Dis 2000; 35: 80–88.
38.
Port FK, Ashby VB, Dhingra RK, Roys EC, Wolfe RA: Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 2002; 13: 1061–1066.
39.
Zoccali C, Torino C, Tripepi G, Mallamaci F: Assessment of obesity in chronic kidney disease: what is the best measure? Curr Opin Nephrol Hypertens 2012; 21: 641–646.
40.
Kimachi M, Fukuma S, Yamazaki S, Yamamoto Y, Akizawa T, Akiba T, Saito A, Fukuhara S: Minor elevation in c-reactive protein levels predicts incidence of erythropoiesis-stimulating agent hyporesponsiveness among hemodialysis patients. Nephron 2015; 131: 123–130.
41.
Sumida K, Yamagata K, Iseki K, Tsubakihara Y: Different impact of hemodialysis vintage on cause-specific mortality in long-term hemodialysis patients. Nephrol Dial Transplant 2016; 31: 298–305.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.